Advances in evaluation of primary brain tumors
- PMID: 18514080
- DOI: 10.1053/j.semnuclmed.2008.02.005
Advances in evaluation of primary brain tumors
Abstract
The evaluation of primary brain tumor is challenging. Neuroimaging plays a significant role. At diagnosis, imaging is needed to establish a differential diagnosis, provide prognostic information, as well as direct biopsy. After the initial treatment, imaging is needed to distinguish recurrent disease from treatment-related changes such as radiation necrosis. In low-grade gliomas, this also includes monitoring anaplastic transformation into high-grade tumors. Recently, targeted treatments have been an extremely active area of research. Evaluation in clinical trials of such targeted treatments demands advanced roles of imaging such as treatment planning, monitoring response, and predicting treatment outcomes. Current clinical gold standard magnetic resonance imaging provides superior structural detail but poor specificity in identifying viable tumors in treated brain with surgery/radiation/chemotherapy. (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is capable of identifying anaplastic transformation and has prognostic value. The sensitivity and specificity of FDG in evaluating recurrent tumor and treatment-induced changes can be significantly improved by coregistration with magnetic resonance imaging and potentially by delayed imaging 3 to 8 hours after injection. Amino acid PET tracers can be more sensitive than FDG in imaging some recurrent tumors, in particular recurrent low-grade tumors. They are also promising for differentiating between recurrent tumors and treatment-induced changes. Newer PET tracers to image important aspects of tumor biology have been actively studied. Tracers for imaging membrane transport such as (18)F-choline have shown promise in differential diagnosis. (18)F-labeled nucleotide analogs such as 3'-deoxy-3'-[(18)F]-fluorothymidine (FLT) and (18)F-FMAU have been developed to image proliferation. The use of FLT has demonstrated prognostic power in predicting treatment response in patients treated with an antiangiogenic agent. Tracers for imaging hypoxia such as (18)F-FMISO have been studied and appear promising in providing prognostic information as well as planning treatment.
Similar articles
-
Molecular imaging (PET) of brain tumors.Neuroimaging Clin N Am. 2009 Nov;19(4):625-46. doi: 10.1016/j.nic.2009.08.012. Neuroimaging Clin N Am. 2009. PMID: 19959009
-
Clinical applications of PET in brain tumors.J Nucl Med. 2007 Sep;48(9):1468-81. doi: 10.2967/jnumed.106.037689. Epub 2007 Aug 17. J Nucl Med. 2007. PMID: 17704239 Review.
-
Neuronuclear assessment of patients with epilepsy.Semin Nucl Med. 2008 Jul;38(4):227-39. doi: 10.1053/j.semnuclmed.2008.02.004. Semin Nucl Med. 2008. PMID: 18514079 Review.
-
Imaging gliomas with positron emission tomography and single-photon emission computed tomography.Semin Nucl Med. 2003 Apr;33(2):148-62. doi: 10.1053/snuc.2003.127304. Semin Nucl Med. 2003. PMID: 12756647 Review.
-
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.J Nucl Med. 2005 Jun;46(6):945-52. J Nucl Med. 2005. PMID: 15937304
Cited by
-
Comparative evaluation of 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma.J Neurooncol. 2024 Jan;166(1):195-201. doi: 10.1007/s11060-023-04534-w. Epub 2023 Dec 31. J Neurooncol. 2024. PMID: 38160415
-
Dexamethasone suppression for 18F-FDG PET/CT to localize ACTH-secreting pituitary tumors.Cancer Imaging. 2023 Sep 12;23(1):85. doi: 10.1186/s40644-023-00600-8. Cancer Imaging. 2023. PMID: 37700359 Free PMC article.
-
The Use of 18F-FET-PET-MRI in Neuro-Oncology: The Best of Both Worlds-A Narrative Review.Diagnostics (Basel). 2022 May 11;12(5):1202. doi: 10.3390/diagnostics12051202. Diagnostics (Basel). 2022. PMID: 35626357 Free PMC article. Review.
-
PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.Cancers (Basel). 2022 Feb 22;14(5):1103. doi: 10.3390/cancers14051103. Cancers (Basel). 2022. PMID: 35267411 Free PMC article. Review.
-
The combined use of EphA2/MMP-2 expression and MRI findings contributes to the determination of cerebral glioma grade.Oncol Lett. 2019 Nov;18(5):5607-5613. doi: 10.3892/ol.2019.10912. Epub 2019 Sep 24. Oncol Lett. 2019. PMID: 31620202 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical